Natco Pharma Ltd.
Price
Daily candles · NSEPrice history isn’t available for this scrip.
What the numbers say
- Good return on equity: 3-year ROE 23.4%.
- Comfortable leverage: debt-to-equity of 0.08.
- Sales compounded at 14.6% over 3 years.
- Profits convert to cash well (CFO/OP 0.76).
- Trades below its industry P/E (9.9 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- NATCO Pharma launches Carboplatin Injection
The company has launched this product in manufacturing collaboration with Teyro Labs
- NATCO Pharma investing $14 million in eGenesis
The total investment made by NATCO Pharma in eGenesis, Inc. now stands at $22 million
- Natco Pharma gets USFDA's tentative approval for Olaparib tablets
NATCO will be manufacturing Olaparib tablets and its partner Alembic, would be distributing the product in the U.S
- Natco Pharma completes acquisition of additional 13.25% stake in Adcock Ingram
With the completion of this transaction, Natco’s shareholding in Adcock Ingram has increased from 35.75% to 49%
- Natco Pharma gets nod to raise stake in Adcock Ingram to 49%
The acquisition is valued at Rs 1,069 crore at the prevailing exchange rate
- Natco Pharma gets nod to invest up to Rs 1,400 crore in NPSAPL
The investment is expected to be completed before the end of July of 2026
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 4,078 | 4,430 | 3,999 | 2,707 | 1,945 |
| Other income | 298 | 357 | 128 | 129 | 99 |
| Total Income | 4,376 | 4,786 | 4,127 | 2,836 | 2,044 |
| Expenditure | 2,642 | 2,236 | 2,247 | 1,795 | 1,681 |
| Operating Profit | 1,734 | 2,551 | 1,880 | 1,040 | 363 |
| Interest | 37 | 24 | 19 | 15 | 18 |
| Depreciation | 207 | 235 | 187 | 164 | 143 |
| Profit before tax | 1,491 | 2,291 | 1,674 | 862 | 202 |
| Tax | 119 | 408 | 285 | 147 | 32 |
| Net Profit | 1,372 | 1,883 | 1,388 | 715 | 170 |
| EPS (₹) | 79.20 | 105.26 | 77.34 | 39.18 | 9.32 |
| Net margin % | 33.6 | 42.5 | 34.7 | 26.4 | 8.7 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 36 | 36 | 36 | 37 | 37 |
| Reserves | 9,185 | 7,571 | 5,817 | 4,837 | 4,224 |
| Net worth | 9,221 | 7,607 | 5,853 | 4,874 | 4,260 |
| Total sources | 9,393 | 7,687 | 5,933 | 4,962 | 4,369 |
| Net block | 2,803 | 2,698 | 2,491 | 2,427 | 2,312 |
| Capital work in progress | 294 | 225 | 137 | 64 | 130 |
| Investments | 3,271 | 708 | 679 | 471 | 385 |
| Inventory | 909 | 766 | 701 | 743 | 762 |
| Debtors | 881 | 1,247 | 1,189 | 856 | 621 |
| Cash & bank | 1,551 | 2,176 | 953 | 546 | 206 |
| Book value (₹) | 515.15 | 424.97 | 326.99 | 267.06 | 233.44 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 1,768 | 1,697 | 1,212 | 849 | 47 |
| From investing | -2,082 | -1,415 | -1,033 | -477 | -5 |
| From financing | 298 | -211 | -247 | -363 | 35 |
| Net change in cash | -16 | 72 | -68 | 9 | 76 |
| Free cash flow | -313 | 282 | 179 | 372 | 41 |
| Closing cash | 199 | 120 | 70 | 132 | 111 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 17.2 | 32.8 | 30.1 | 18.1 | 4.9 |
| ROE % | 16.3 | 28.0 | 25.9 | 15.7 | 4.1 |
| PAT margin % | 29.2 | 39.5 | 32.0 | 24.8 | 7.7 |
| EBIT margin % | 32.5 | 48.6 | 39.1 | 30.4 | 9.9 |
| Debt / equity | 0.08 | 0.04 | 0.06 | 0.03 | 0.09 |
| Current ratio | 3.01 | 5.59 | 4.14 | 4.39 | 3.50 |
| Interest cover | 41.62 | 96.87 | 88.16 | 60.44 | 12.42 |
| Sales growth % | -7.9 | 10.8 | 47.7 | 39.2 | -5.2 |
| Dividend per share (₹) | 5.00 | 6.00 | 9.50 | 5.50 | 4.50 |
| Payout % | 6.3 | 5.7 | 12.2 | 14.0 | 48.3 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Natco Pharma Ltd. (NATCOPHARM) last traded at ₹785.15 on the NSE, up +0.09% on the session. Prices on this page are indicative and for information only.
Natco Pharma Ltd. has traded between ₹773.60 and ₹1,226.80 over the last 52 weeks on the NSE.
Natco Pharma Ltd. has a market capitalisation of about ₹14,054 crore.
Natco Pharma Ltd. trades at a P/E of 9.9, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for NATCOPHARM from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Natco Pharma Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in